Breast

Sacituzumab govitecan with or without pembrolizumab in TNBC

The Dana-Farber’s Breast Oncology Center shared on X:

“Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative (TNBC) that is PD-L1-negative offering sacituzumab govitecan with or without pembrolizumab.

For more info call 877-338-7425 or visit here.”

Source: Dana-Farber’s Breast Oncology Center/X

cancer Dana-Farber’s Breast Oncology Center Metastatic Triple Negative Breast Cancer OncoDaily Oncology pembrolizumab Sacituzumab govitecan TNBC